{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:32:28Z","timestamp":1790814748396,"version":"4.1.0"},"reference-count":26,"publisher":"American Medical Association (AMA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>Clonal hematopoiesis (CH) has been associated with development of atherosclerosis and leukemia and worse survival among patients with cancer; however, the association with cancer therapy efficacy, in particular immune checkpoint blockade (ICB), and toxicity has not yet been established. Given the widespread use of ICB and the critical role hematopoietic stem cell\u2013derived lymphocytes play in mediating antitumor responses, CH may be associated with therapeutic efficacy and hematologic toxicity.<\/jats:p><\/jats:sec>Objective<\/jats:title>To determine the association between CH and outcomes, hematologic toxicity, and therapeutic efficacy in patients with metastatic gastrointestinal tract cancers being treated with systemic therapy, both in the first-line metastatic treatment setting and in ICB.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This retrospective cohort study included 633 patients with stage IV colorectal (CRC) and esophagogastric (EGC) cancer who were treated with first-line chemotherapy and\/or ICB at Memorial Sloan Kettering Cancer Center. Patients underwent matched tumor and peripheral blood DNA sequencing using the Memorial Sloan Kettering\u2013Integrated Mutation Profiling of Actionable Cancer Targets next-generation sequencing assay between January 1, 2006, and December 31, 2020.<\/jats:p><\/jats:sec>Exposures<\/jats:title>Clonal hematopoiesis\u2013related genetic alterations were identified by next-generation sequencing of patients\u2019 tumor and normal blood buffy coat samples, with a subset of these CH alterations annotated as likely putative drivers (CH-PD) based upon previously established criteria.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>Patients with CH and CH-PD in peripheral blood samples were identified, and these findings were correlated with survival outcomes (progression-free survival [PFS] and overall survival [OS]) during first-line chemotherapy and ICB, as well as baseline white blood cell levels and the need for granulocyte colony-stimulating factor (G-CSF) support.<\/jats:p><\/jats:sec>Results<\/jats:title>Among the 633 patients included in the study (390 men [61.6%]; median age, 58 [IQR, 48-66] years), the median age was 52 (IQR, 45-63) years in the CRC group and 61 (IQR, 53-69) years in the EGC group. In the CRC group, 161 of 301 patients (53.5%) were men, compared with 229 of 332 patients (69.0%) in the EGC group. Overall, 62 patients (9.8%) were Asian, 45 (7.1%) were Black or African American, 482 (76.1%) were White, and 44 (7.0%) were of unknown race or ethnicity. Presence of CH was identified in 115 patients with EGC (34.6%) and 83 with CRC (27.6%), with approximately half of these patients harboring CH-PD (CRC group, 44 of 83 [53.0%]; EGC group, 55 of 115 [47.8%]). Patients with EGC and CH-PD exhibited a significantly worse median OS of 16.0 (95% CI, 11.6-22.3) months compared with 21.6 (95% CI, 19.6-24.3) months for those without CH-PD (P<\/jats:italic>\u2009=\u2009.01). For patients with CRC and EGC, CH and CH-PD were not associated with PFS differences in patients undergoing ICB or first-line chemotherapy. Neither CH nor CH-PD were correlated with baseline leukocyte levels or increased need for G-CSF support.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>These findings suggest CH and CH-PD are not directly associated with the treatment course of patients with metastatic gastrointestinal tract cancer receiving cancer-directed therapy.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2022.54221","type":"journal-article","created":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T16:11:02Z","timestamp":1675354262000},"page":"e2254221","source":"Crossref","is-referenced-by-count":18,"title":["Clinical Importance of Clonal Hematopoiesis in Metastatic Gastrointestinal Tract Cancers"],"prefix":"10.1001","volume":"6","author":[{"given":"Bill H.","family":"Diplas","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Ptashkin","sequence":"additional","affiliation":[{"name":"Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne F.","family":"Chou","sequence":"additional","affiliation":[{"name":"Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shalom","family":"Sabwa","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael B.","family":"Foote","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benoit","family":"Rousseau","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillem","family":"Argil\u00e9s","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James Robert","family":"White","sequence":"additional","affiliation":[{"name":"Resphera Biosciences LLC, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlin M.","family":"Stewart","sequence":"additional","affiliation":[{"name":"Meyer Cancer Center, Weill Cornell Medicine, New York, New York"},{"name":"New York Genome Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Bolton","sequence":"additional","affiliation":[{"name":"Department of Medicine, Washington University Medical School, St Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sree B.","family":"Chalasani","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avni M.","family":"Desai","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoe","family":"Goldberg","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Gu","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Shcherba","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Zervoudakis","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Cercek","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rona","family":"Yaeger","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil H.","family":"Segal","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David H.","family":"Ilson","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey Y.","family":"Ku","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmet","family":"Zehir","sequence":"additional","affiliation":[{"name":"Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marinela","family":"Capanu","sequence":"additional","affiliation":[{"name":"Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yelena Y.","family":"Janjigian","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Luis A.","family":"Diaz","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven B.","family":"Maron","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2023,2,2]]},"reference":[{"issue":"1","key":"zoi221533r1","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1182\/blood-2015-03-631747","article-title":"Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes.","volume":"126","author":"Steensma","year":"2015","journal-title":"Blood"},{"issue":"26","key":"zoi221533r2","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.1056\/NEJMoa1409405","article-title":"Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence.","volume":"371","author":"Genovese","year":"2014","journal-title":"N Engl J Med"},{"issue":"3","key":"zoi221533r3","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.stem.2017.07.010","article-title":"Therapy-related clonal hematopoiesis in patients with non-hematologic cancers is common and associated with adverse clinical outcomes.","volume":"21","author":"Coombs","year":"2017","journal-title":"Cell Stem Cell"},{"issue":"5","key":"zoi221533r4","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.stem.2018.10.004","article-title":"PPM1D mutations drive clonal hematopoiesis in response to cytotoxic chemotherapy.","volume":"23","author":"Hsu","year":"2018","journal-title":"Cell Stem Cell"},{"issue":"7540","key":"zoi221533r5","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/nature13968","article-title":"Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia.","volume":"518","author":"Wong","year":"2015","journal-title":"Nature"},{"issue":"26","key":"zoi221533r6","doi-asserted-by":"publisher","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","article-title":"Age-related clonal hematopoiesis associated with adverse outcomes.","volume":"371","author":"Jaiswal","year":"2014","journal-title":"N Engl J Med"},{"issue":"6","key":"zoi221533r7","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.stem.2018.10.013","article-title":"Inhibition of inflammatory signaling in Tet2 mutant preleukemic cells mitigates stress-induced abnormalities and clonal hematopoiesis.","volume":"23","author":"Cai","year":"2018","journal-title":"Cell Stem Cell"},{"issue":"6327","key":"zoi221533r8","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1126\/science.aag1381","article-title":"Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice.","volume":"355","author":"Fuster","year":"2017","journal-title":"Science"},{"issue":"8","key":"zoi221533r9","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1016\/j.stem.2021.03.002","article-title":"Chronic infection drives Dnmt3a-loss-of-function clonal hematopoiesis via IFN? signaling.","volume":"28","author":"Hormaechea-Agulla","year":"2021","journal-title":"Cell Stem Cell"},{"issue":"7706","key":"zoi221533r10","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1038\/s41586-018-0125-z","article-title":"Microbial signals drive pre-leukaemic myeloproliferation in a Tet2-deficient host.","volume":"557","author":"Meisel","year":"2018","journal-title":"Nature"},{"issue":"6","key":"zoi221533r11","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1038\/s41591-021-01371-0","article-title":"Hematopoietic mosaic chromosomal alterations increase the risk for diverse types of infection.","volume":"27","author":"Zekavat","year":"2021","journal-title":"Nat Med"},{"key":"zoi221533r12","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.exphem.2017.08.001","article-title":"Tet2 restrains inflammatory gene expression in macrophages.","volume":"55","author":"Cull","year":"2017","journal-title":"Exp Hematol"},{"issue":"8","key":"zoi221533r13","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/j.jacc.2017.12.037","article-title":"Tet2-mediated clonal hematopoiesis accelerates heart failure through a mechanism involving the IL-1\u00df\/NLRP3 inflammasome.","volume":"71","author":"Sano","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"7569","key":"zoi221533r14","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/nature15252","article-title":"Tet2 is required to resolve inflammation by recruiting Hdac2 to specifically repress IL-6.","volume":"525","author":"Zhang","year":"2015","journal-title":"Nature"},{"issue":"4","key":"zoi221533r15","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1038\/s41588-020-0595-4","article-title":"DNA methylation disruption reshapes the hematopoietic differentiation landscape.","volume":"52","author":"Izzo","year":"2020","journal-title":"Nat Genet"},{"issue":"10","key":"zoi221533r16","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1182\/blood.2021014108","article-title":"Clonal hematopoiesis is associated with improved survival in patients with metastatic colorectal cancer from the FIRE-3 trial.","volume":"139","author":"Arends","year":"2022","journal-title":"Blood"},{"issue":"6280","key":"zoi221533r17","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1126\/science.aaf1490","article-title":"Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade.","volume":"351","author":"McGranahan","year":"2016","journal-title":"Science"},{"issue":"6382","key":"zoi221533r18","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade.","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"issue":"3","key":"zoi221533r19","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.jmoldx.2014.12.006","article-title":"Memorial Sloan Kettering\u2013Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology.","volume":"17","author":"Cheng","year":"2015","journal-title":"J Mol Diagn"},{"issue":"7","key":"zoi221533r21","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1093\/bioinformatics\/btt755","article-title":"MSIsensor: microsatellite instability detection using paired tumor-normal sequence data.","volume":"30","author":"Niu","year":"2014","journal-title":"Bioinformatics"},{"key":"zoi221533r22","doi-asserted-by":"publisher","DOI":"10.1200\/PO.17.00084","article-title":"Reliable pan-cancer microsatellite instability assessment by using targeted next-generation sequencing data.","volume":"2017","author":"Middha","year":"2017","journal-title":"JCO Precis Oncol"},{"issue":"11","key":"zoi221533r24","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1038\/s41588-020-00710-0","article-title":"Cancer therapy shapes the fitness landscape of clonal hematopoiesis.","volume":"52","author":"Bolton","year":"2020","journal-title":"Nat Genet"},{"issue":"11","key":"zoi221533r25","doi-asserted-by":"publisher","first-page":"3208","DOI":"10.1158\/1055-9965.EPI-08-0512","article-title":"Molecular characterization of MSI-H colorectal cancer by MLHI promoter methylation, immunohistochemistry, and mismatch repair germline mutation screening.","volume":"17","author":"Poynter","year":"2008","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"44","key":"zoi221533r26","doi-asserted-by":"publisher","first-page":"16433","DOI":"10.3748\/wjg.v20.i44.16433","article-title":"Causes and consequences of microsatellite instability in gastric carcinogenesis.","volume":"20","author":"Velho","year":"2014","journal-title":"World J Gastroenterol"},{"key":"zoi221533r20","unstructured":"Genomic profiling in cancer patients. ClinicalTrials.gov identifier: NCT01775072. Updated December 29, 2022. Accessed January 12, 2023. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01775072"},{"key":"zoi221533r23","doi-asserted-by":"crossref","unstructured":"Ziegler? J, Hechtman? JF, Ptashkin? R, . MiMSI\u2014a deep multiple instance learning framework improves microsatellite instability detection from tumor next-generation sequencing.? bioRxiv. Preprint posted online September 18, 2020. doi:10.1101\/2020.09.16.299925?","DOI":"10.1101\/2020.09.16.299925"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2800900\/diplas_2023_oi_221533_1674492358.63165.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T16:11:08Z","timestamp":1675354268000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2800900"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,2]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.54221","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,2]]}}}